A new first-line chemotherapy regimen of prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) yields a high complete metabolic response (CMR) rate with acceptable toxicity in older patients with classical Hodgkin lymphoma (cHL), according to research published in Blood.
This article describes research done by the Childhood Cancer Survivor Study of St. Jude Children’s Research Hospital and CARDIA, which stands for “Coronary Artery Risk Development in Young Adults.” These two organizations combined their data bases to create an in-depth study of the specific risks for childhood cancer survivors. The results are concerning, and they underline the need for early and frequent observation post treatment.
The research was presented in October, 2022 at the International Symposium on Hodgkin Lymphoma and earlier, at the ASCO (American Society for Clinical Oncology) Annual Meeting in 2021. A common chemotherapy drug used to treat Hodgkin lymphoma conferred a significantly increased risk of breast cancer among women treated during adolescence and adulthood, a large retrospective study showed.
This article in HemOnc Today describes a recent study that evaluated the use of specific biomarkers, namely global longitudinal strain (GLS) and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) to identify childhood cancer survivors who may be at risk for cardiomyopathy. The study was done through the St. Jude Lifetime Cohort study.
Sometimes, moving our bodies is the LAST thing we want to do. Cancer survivorship can be exhausting. Fatigue is one of the most common effects of cancer treatment. And, the more late effects begin to pile up, the more tired we become, and the more likely we are to succumb to the couch. But there are many, many reasons why we shouldn’t.
Even a small amount of exercise can have a significant impact. Just about everyone can benefit from a daily walk.
This research paper takes a look at the risk of breast cancer from doxorubicin exposure in female survivors of Hodgkin lymphoma who are between the ages of 15-50 years of age and five years post treatment. The period of treatment was between 1975 and 2008. The study was first presented in 2021 at the ASCO Annual Meeting.
Of note is that the authors found an increased risk of breast cancer in this cohort independent of whether or not radiation was also a part of the treatment protocol.
When thinking about cancer research, many people think of studies focused on evaluating new or better ways to treat the cancer itself. What may not come to mind is a type of research known as “survivorship research.”
Men with breast cancer tend to have a worse prognosis than women, as they commonly have more advanced disease at diagnosis. While many practitioners utilize mammography screening for women, there is less awareness of recommendations regarding screening for men.
Patients with cancer had a higher rate of acute MI when presenting to the ED with chest pain.